Pathways to faster medicine approval

Get an overview of established and new pathways in the EU, UK and US

Get course info
No available dates

On location

English

5,800 DKK ex VAT

(app. 780 EUR ex VAT)

50% DISCOUNT FOR PUBLIC INSTITUTIONS
Home > Courses > Pathways to faster medicine approval

Summary

The demand for shorter regulatory review timelines during COVID-19 has proven that it is crucial for the life science industry to look into alternative regulatory pathways.

Get an overview of the EU, UK and US approach at this course where experts from authorities and the industry share their experiences and perspectives. Also, we will discuss the criteria that apply including what kind of medical need would justify the different options.
 

Keywords

  • Alternative regulatory approvals
  • Approval timelines
  • Rolling review
  • Medical need
  • Shorter review timelines
  • Emergency use
  • Accelerated review

    Hi! 

    Do you need help choosing the right course? 

    We are ready to help you at +45 39 27 60 60 or contact@atriumcph.com 

    Stay tuned with Atrium's newsletter 


Save information for later
Read more

Course leader & lecturers

  • Inger Mollerup
    Course leader
    Independent Regulatory Consultant
    Inger Mollerup Regulatory Consulting
  • Jens Heisterberg
    Lecturer
    VP, Regulatory Policy and Intelligence
    Novo Nordisk A/S
  • Lucia D'Apote
    Lecturer
    EUCOPE R&D Topic Lead, Scientific advice, PRIME, RWE/Big data
    Amgen Ltd., UK
  • Robert Babilon
    Lecturer
    President
    Prosoft Clinical
  • Christian Schneider
    Lecturer
    Head of Biopharma Excellence and Chief Medical Officer (Biopharma)
    PharmaLex Denmark A/S
  • Ida Sofie Jensen
    Lecturer
    CEO of The Danish Association of the Pharmaceutical Industry
    Lif
See all

Is this course for you?

This course is for project and regulatory leaders as well as pharmaceutical specialists with an advanced level of regulatory experience (minimum 2 years).

What you will learn

  1. Knowledge of alternative regulatory pathways in the EU, UK and US
  2. Dynamics of development of medicines with shortened review times
  3. Preconditions for approval of medicines based on less clinical data than normally required
  4. Appliance of emergency use authorisations
  5. Use of temporary regulatory approvals

What your company will get

  1. An employee who understands the situations that qualify for abbreviated and special pathways in the EU, UK and US jurisdictions.
  2. An employee who knows the principles of development of medicines with shortened review times.
  3. An employee who is familiar with alternative approval pathways, emergency use authorisations and temporary approvals.

Course leader

Inger Mollerup
Independent Regulatory Consultant
Inger Mollerup Regulatory Consulting

Lecturers

Jens Heisterberg
VP, Regulatory Policy and Intelligence
Novo Nordisk A/S
Lucia D'Apote
EUCOPE R&D Topic Lead, Scientific advice, PRIME, RWE/Big data
Amgen Ltd., UK
Robert Babilon
President
Prosoft Clinical
Christian Schneider
Head of Biopharma Excellence and Chief Medical Officer (Biopharma)
PharmaLex Denmark A/S
Ida Sofie Jensen
CEO of The Danish Association of the Pharmaceutical Industry
Lif

You may also be interested in these courses

Want to know more or need help?

Contact Client Manager Mette Ribergaard Rasmussen at +45 39 15 09 30

Send me a message
GO TO FAQ